10 Industry Outlook & Market Opportunity
🔹Global Pharma Market Growth:
✅ $1,635 Bn in 2023 → $2,251 Bn by 2028 (CAGR 6.6%)
✅ Regulated pharma market to dominate with 77% share by 2028
🔹CDMO Market Expansion:
✅ CDMO market growing at 7.7% CAGR, faster than the overall pharma industry
✅ US accounts for ~40% of the global CDMO/CMO market
🔹Emerging Market Growth:
✅ ₹376.3 Bn in 2023 → ₹541 Bn by 2028 (CAGR 7.5%)
✅ Rising demand for specialty & complex generics in CIS, LATAM & SE Asia
🔹Government & Regulatory Tailwinds Supporting Growth:
✅ US Buy American Act (BAA) compliance creating CDMO opportunities
✅ PLI Scheme for bulk drugs & specialty generics in India
✅ Regulatory push for local manufacturing in key export markets
📌 Senores Pharma is positioned to capitalize on the booming CDMO sector, growing demand for specialty generics, and increasing global pharma spending
8 Management Guidance & Future Plans
📌 Order Book & Key Growth Drivers
🔹Strong pipeline with CDMO contracts & regulated market expansion
🔹51 new products in the pipeline, 5 launches in Q4
🔹Emerging markets expansion – 10x growth potential
🔹CDMO/CMO revenue target: $25-30M in FY26
🔹Injectables & API backward integration for cost efficiency
🔹₹200 Cr CapEx planned – Greenfield plant included
🔹Diversification strategy to reduce customer & tariff risks
📝 Senores Q3FY25 ConCall Highlights (Feb 5, 2025)
📊 Financial & Business Growth Guidance :
🔹FY25 revenue target: ₹410-₹440 Cr
🔹FY26 revenue target: ₹670-₹700 Cr
🔹50%-60% top-line growth expected in FY26
🔹PAT expected to double in FY26
🔹EBITDA Margin Expansion: Targeting 28-30%
Capacity Utilization:
🔹FY26: 75% utilization of the expanded API & injectables facility
🔹FY27: 100% utilization with new CDMO contracts
🔹CDMO Business Contribution: Projected to contribute $25-30M in revenue for FY26
Major CDMO Contracts Secured (Q3 FY25):
🔹US-Based Generic Pharma Company – CDMO contract for oral solid formulations
🔹Large European Pharma Player – Long-term CDMO deal for high-margin specialty generics
🔹Emerging Market Supply Contracts – Expanding into CIS, Latin America & Southeast Asia
🔹New CDMO Client Approvals: Additional 5-6 customers in the pipeline
🔹Expanding Portfolio: 28 CGT designated products in pipeline for market exclusivity
Execution Timeline
🔹₹200+ Cr worth of orders to be completed in the next 6-9 months
🔹Accelerated regulatory approvals improving new product pipeline execution
🔹USFDA Inspection Readiness: Ensuring continued compliance & audit preparedness
🔹Emerging Market Growth Acceleration: 131 new filings planned across various geographies
🔄 Order Pipeline Growth & Market Expansion
🔹Growing demand in CDMO, injectables & emerging markets
🔹Exports: Expanding regulated market penetration in US, Canada & UK
🔹Targeting 5 New Market Entries in FY26
🔹Government Contracts Expansion: Exploring opportunities under US Buy American Act compliance
🏭 Expansion & Growth Plans
🔹Chhatral API Facility (FY26): Expanding API production from 25 MTPA to 169 MTPA
🔹Injectables Expansion (US & India): Sterile injectable production ramp-up
🔹New Greenfield Manufacturing Facility (India): Strengthening presence in mid-tier emerging markets
🔹Scaling Production Capabilities: Planned capacity increase to support CDMO & regulated market demand
📉 Competitive Positioning & Market Strength
🔹Rapidly growing player in CDMO & complex generics
🔹80%+ of business from repeat orders, demonstrating strong client retention
🔹R&D Expansion: New research initiatives to strengthen complex formulation pipeline
🌍 Exports & International Market Expansion
🔹Targeting deeper penetration in regulated markets (US, Canada, UK)
🔹Scaling up API & injectables exports to emerging markets (CIS, Latin America, SE Asia)
🔹Entering 2-3 New High-Potential Markets in FY26
🔹New Distribution Partnerships: Strengthening sales channels across strategic geographies
📢 Senores Pharmaceuticals is set for strong growth with capacity expansion, increasing CDMO contracts, aggressive market expansion, strategic acquisitions, and an enhanced focus on R&D-driven high-margin products!
6 Competitive Landscape, Market Positioning & Key Strengths
🌍 Industry Ranking & Competitors:
🔹Ranked as a Fast-Growing Player in the Global Pharmaceutical & CDMO Sector
🔹Lupin (Strong presence in regulated generics & CDMO partnerships)
🔹Aurobindo Pharma (Well-established in regulated markets with a vast ANDA portfolio)
🔹Dr. Reddy’s (Strong CDMO capabilities & presence in high-growth markets)
📈 Market Positioning & Growth Strategy:
🔹Expanding CDMO/CMO Business – 21 commercialized products, 69 in pipeline
🔹Targeting niche generics & high-margin specialty formulations in regulated markets
🔹Emerging Market Growth Strategy – Strengthening presence in CIS, Latin America, & Southeast Asia
🚀 Export Market Expansion:
🔹Growing presence in US, Canada, UK, and 40+ emerging markets
🔹Dedicated regulatory teams to accelerate approvals & international market penetration
💡 Key Strengths of Senores Pharmaceuticals:
1️⃣ Specialty & Complex Product Portfolio – Rapidly built a differentiated portfolio for Regulated Markets
2️⃣ Long-Term Market Arrangements – Established partnerships with pharmaceutical companies in Regulated Markets
3️⃣ Strong Presence in Emerging Markets – Expanding portfolio with specialty & complex products
4️⃣ Robust R&D Capabilities – Driving innovation in niche & high-margin formulations
5️⃣ Advanced Manufacturing Facilities – USFDA-approved plant in the US for Regulated & Semi-Regulated Markets + WHO-GMP certified Indian facility for Emerging Markets
6️⃣ Experienced & Dedicated Management Team
📌 Senores Pharma is strengthening its global footprint with a growing CDMO business, niche product focus, and a strong foundation in R&D and global market reach.
4 Expansion & Growth Strategy
🏭 Current Manufacturing Facilities:
1️⃣ Atlanta, US (USFDA-approved): 1.2 billion units/year (Tablets & Capsules) | Utilizable ~50%
2️⃣ Ahmedabad, India (WHO-GMP): 1.9 billion units/year (Oral Solids + Beta Lactam Orals) + 50 million injectables/year | Utilizable ~65-70%
3️⃣ API Facility (Naroda, India): Manufacturing 16 APIs | Capacity Expansion Planned
🚀 Planned Expansion:
🔹Chhatral API Facility (Under Development): Expanding API capacity from 25 MTPA to 169 MTPA | Expected Completion: FY26
🔹Injectables Expansion (Atlanta, US): Sterile Injectable Production to commence | Expected Completion: 18-24 months
🔹New Greenfield Manufacturing (India): Expansion to serve mid-tier emerging markets | Location & Capacity TBA
📊 Total Installed Capacity: 3.15 billion+ units (including injectables)
📊 Planned Expansion Impact: Significant increase in API production + injectables capacity
📌Strategic capacity expansion = Higher revenue potential & stronger global market presence.
2 Business Model - How Does Senores Make Money?
💊 Pharmaceutical Manufacturing & CDMO/CMO - Core Offerings:
1️⃣ Regulated Market Pharma Business -Developing & manufacturing niche pharmaceutical formulations for US, Canada, and UK markets.
2️⃣ Emerging Market Pharma Business - Expanding presence in 40+ countries with a growing portfolio of specialty generics.
3️⃣ Contract Development & Manufacturing (CDMO/CMO) - Customized formulation, development & manufacturing for global pharma companies.
4️⃣ Critical Care Injectables & API Manufacturing - Backward integration for cost efficiency & supply chain control.
💊Product Portfolio & Business Verticals:
🔹Regulated Markets (US, Canada, UK):
1️⃣ Branded Generics & Complex Formulations - Own & partnered ANDAs (22 commercialized, 24 approved, 51 in pipeline).
2️⃣ Competitive Generic Therapy (CGT) Products - 28 pipeline CGT opportunity molecules.
3️⃣ CDMO/CMO Partnerships - Providing end-to-end drug development, formulation & contract manufacturing services to global pharma giants.
🔹Emerging Markets (40+ countries):
1️⃣ Diverse Portfolio – 267 registered products across CNS, Cardiovascular, Pain Management & Anti-infectives.
2️⃣ Multiple Market Models – Distributor partnerships, own branded generics, & licensing agreements.
🔹API & Injectable Business:
1️⃣ API Manufacturing – Producing critical APIs for regulated & emerging markets.
2️⃣ Critical Care Injectables – Direct hospital supplies via multi-specialty chains (55 products launched).
📌 Senores is a fully integrated pharmaceutical player, leveraging its strong R&D, CDMO expansion, and global market presence for exponential growth
🏥Senores Pharmaceuticals Ltd - A Detailed Analysis
-Senores Pharma is a research driven pharmaceutical company with a strong presence in regulated and emerging markets.
-With robust financial performance and aggressive product pipeline expansion, it is on track to double its revenue in the next two years.
📊 52-Week High / Low: ₹645 / ₹435
💰 Market Cap: ₹2,590 Cr
credit : Sovrenn
One CDMO company Detail analsysis coming up in Few Minutes Stay tuned Here
Читать полностью…
Strong company posted Good quaterly numbers will share few image 👇
Читать полностью…
Short term trading , positional trading
And learning priceaction join now @wealthcreator7
Stock SIP, long term investment don't miss to join @stocksip
Corporate update, quaterely result, management guidance @companyupdate
Daily one company Fundamental analaysis in detail daily
@fundamental3
US STOCK Chart study for more detail visit
@Us_stock3
Order Book, capex and stock information in detail @stockinfo33
Stock market statics and information @stockinfo3
All IPO Updates Live @ipoinfo3
All conference call and detail stock study @nilfaldu
Coming up next Good Quaterly Result will try to share
Читать полностью…
Bhansali added that stable cash flow coming from the company's B2B operation in the US is aiding investments in brands and retail stores in India.
In the US, Goldiam primarily caters to middle- to premium-income retailers.
"That (support from the US business) is allowing us to invest in a brand and a retail store in India," he explained.
"We have plans to enhance the store fleet to 150 to 200 stores within 3 to 5 years.
Again, that will be pulled in as a result of the first increase in COCO (Company Owned, Company Operated) stalls, but down the road, the next couple of calendar years, opening up to franchises as well.
Today, 100% of all our plans are COCO stalls and every fleet expansion that we are currently looking at will be undertaken
by equity at Goldiam itself," Bhansali mentioned.
When asked about where he plans to get the funds for this store expansion, Anmol Bhansali said that the company is yet to discuss the long-term plans.
However, for FY25, the funding for opening stores in 2025 will most likely be done through internal accruals.
"At the moment there are no discussions. For this calendar year, we will most likely be
looking at internal accruals unless we have an outstanding opportunity available to us.
It's dependent on what the board sees value being available in and then the performance of Origem, how we want to fuel its growth and how fast we want to fuel its growth to take it further," he added.
#Goldiam International aims to expand store fleet to around 150–200 within next three to five years
Читать полностью…
Textiles
Export of ready-made garments from India in January 2025 was at the highest level in the last 34 months.
Must Join 👇
@wealthcreator7
11 Key Risks & Challenges
⚠️ Regulatory Compliance Risks – Continuous adherence to USFDA & global regulatory norms is critical
⚠️ Pricing Pressure & Competition – Generic price erosion in the US & regulated markets could impact margins
⚠️ Customer Concentration Risk – Top 5 clients contribute ~65% of revenue, making diversification essential
⚠️ Debt & Leverage Risk – D/E at 1.26, higher than ideal, but manageable for expansion
⚠️ Global Economic Conditions – Slowdowns in key export markets could impact revenue growth
📌Senores Pharma’s strong CDMO contracts, diversification strategy, and expanding product portfolio help mitigate risks
9 Valuation & Key Metrics
📢 Does It Pass Fundamental Investment Screening?
Refer below image
✅ Passes 4/9 Key Investment Filters
❌ Fails in P/E, D/E & PB Ratio
(NO buy/Sell recommendation)
📊 Positives:
✅ Exceptional Profit Growth (162.6% YoY) -Strong earnings expansion
✅ Strong ROE (25.2%) - Efficient capital utilization ✅ No Pledged Shares -Zero risk of share dilution ✅ Growing CDMO & API Business - Expansion driving future growth
⚠️ Concerns:
❌High P/E (82.3) - Valuation premium due to growth potential
❌Higher Debt to Equity (1.26) - Expansion driven leverage
❌ROCE (11.5%) Below Ideal - Needs improvement in capital efficiency
NO buy/Sell recommendation.
📌 Senores Pharma is a Not a textbook perfect fundamental stock, but a high-growth business with strong financials with strong profitability & expansion potential. Investors should monitor leverage and efficiency improvements.
7 Financial Performance
📊 Quarterly Performance (Q3 FY25)
🔹Revenue: ₹106.4 Cr (⬆️ 35.2% YoY)
🔹EBITDA: ₹29.1 Cr (⬆️ 91.8% YoY)
🔹EBITDA Margin: 27.3% (⬆️ 810 bps)
🔹Profit Before Tax (PBT): ₹22.5 Cr (⬆️ 128.1% YoY)
🔹Profit After Tax (PAT): ₹17.2 Cr (⬆️ 142.3% YoY)
🔹PAT Margin: 16.1% (⬆️ 710 bps)
🔹Earnings Per Share (EPS): ₹6.14 (vs. ₹2.52 in Q3 FY24)
📈 Nine-Month Performance (9M FY25)
🔹Revenue: ₹288.1 Cr (⬆️ 157% YoY)
🔹EBITDA: ₹74.3 Cr (⬆️ 287% YoY)
🔹EBITDA Margin: 25.8% (⬆️ 870 bps)
🔹Profit Before Tax (PBT): ₹52.9 Cr (⬆️ 305% YoY)
🔹Profit After Tax (PAT): ₹40.7 Cr (⬆️ 162% YoY)
🔹PAT Margin: 14.1% (⬆️ 30 bps)
🔹Earnings Per Share (EPS): ₹14.56 (vs. ₹5.86 in 9M FY24)
💰 Financial Strength
🔹Low Debt: Strong balance sheet with net cash-positive position .
🔹Healthy Order Book: Strong CDMO pipeline ensuring sustained growth.
📌Senores Pharmaceuticals is witnessing robust financial growth, driven by strong CDMO expansion, increasing revenue streams, and a healthy financial position.
5 Senores Key Clients & Partnerships
♻️Long-Term Partnerships Driving Growth
CDMO/CMO Revenue Contribution Growing Rapidly
🔹FY24: CDMO accounted for ~24% of regulated market revenue .
🔹FY25 Target: CDMO revenue expected to reach $25-30 million (~₹210-250 Cr)
📊Top Clients & Contribution:
🔹Top 5 Clients’ Contribution: ~65% of revenue from regulated market
🔹CDMO Business Expanding: 21 commercialized products, 69 in the pipeline
🔹Long-Term Contracts: 5-7 year agreements with leading global pharmaceutical companies
🏆Key Clients (Global Pharma Companies):
1️⃣Ajanta Pharma (Regulated & Emerging Market Partner)
2️⃣Dr. Reddy’s (CDMO/CMO & Emerging Market Distribution)
3️⃣Sun Pharma (API Supply & Emerging Market Business)
4️⃣Cipla (Injectables & Emerging Market Distribution)
5️⃣Mankind Pharma (Regulated & Emerging Market Supply Agreements)
6️⃣Jubilant Cadista (US Market Partnerships & CDMO Business)
7️⃣Ambica, Amici Pharmaceuticals, Cintex, Mint Pharmaceuticals, La Renon, Prasco, RiteMED, Shalina (Various Market Partnerships)
🚀Emerging Partnerships:
🔹Expanding CDMO/CMO deals in US, Canada & UK (Multiple Clients, Details Not Disclosed)
🔹Increased penetration in CIS, Latin America & Southeast Asia (Distributor Agreements in Place)
🏛Government & Institutional Collaborations:
🔹Supplying Critical Care Injectables to Multi-Specialty Hospitals (India & Emerging Markets)
🔹Targeting US Government Supply Contracts via Buy American Act (BAA) Compliance (US Market)
📌 Strong client retention, growing CDMO/CMO partnerships, and an expanding product pipeline position Senores for sustainable long-term growth
3 Revenue Model & Contribution
🔹Revenue Model:
1️⃣ Direct Sales – Supplying pharmaceutical products to distributors, hospitals, and government agencies.
2️⃣ Long-Term Contracts – CDMO/CMO agreements with multinational pharma companies for sustained revenue.
3️⃣ Licensing & Partnership Model – Revenue from licensing out ANDAs and in-licensing partnerships.
🔹Revenue Contribution (By Business Segment):
1️⃣ Regulated Markets (US, Canada, UK): 64%
2️⃣ Emerging Markets (40+ countries): 30%
3️⃣ API & Injectables Business: 6%
🔹Core Raw Materials Used:
1️⃣ Active Pharmaceutical Ingredients (APIs) – Both in-house and outsourced for cost efficiency.
2️⃣ Excipients & Formulation Components –Essential raw materials for tablets, capsules, and injectables.
3️⃣ Packaging Materials – Blister packs, vials, and sterile containers for regulated and emerging markets.
📌 A well-diversified revenue model with strong CDMO partnerships and a global presence ensures sustained growth for Senores!
1 Who is Senores Pharmaceuticals?
📍Company Overview:
🔹Founded: 2017
🔹Headquarters: Ahmedabad, India
🔹Business Model: Research-driven pharmaceutical manufacturing & CDMO/CMO services
🔹Presence: Strong foothold in regulated markets (US, Canada, UK) + 40+ emerging markets
🔹Manufacturing Plants: USFDA-approved facility in Atlanta, US + WHO-GMP facility in India
🔹Total Installed Capacity: 1.2 billion units (US) + 1.9 billion units (India) + 50 million injectables
🔹Market Position: Fast-growing player in global pharmaceuticals, expanding CDMO/CMO presence
🏢 Subsidiaries & Business Divisions:
🔹Senores Pharmaceuticals Inc. (100% Subsidiary) – ANDA holding company for US operations
🔹Havix Group Inc. (66.58% Subsidiary) – CDMO & Generic Formulations for US & Canada
🔹Ratnatris Pharmaceuticals Pvt. Ltd. (69% Subsidiary) – Manufacturing & marketing in emerging markets
📌 With a robust product pipeline, CDMO expansion, and strong regulatory market presence, Senores Pharma is set for explosive growth.
Thats It ALL 5 Part is important
Читать полностью…
Newly Listed Companies with Strong Q3 Numbers:
🟢KRN Heat Exchangers: Down 15% from ATH, valuations still high
🟢Enviro Infra: Down 67%, PE dropped 49 → 29(now decent)
🟢Transrail Lighting: Down 38%, attractive valuations (PE: 27.8)
🟢PN Gadgil: Down 51%, PE de-rated 80→35
☀️ FII BUYING STOCKS
👉15 STOCKS WHERE FII HAVE INCREASED STAKE MORE THAN 5%
1. Mercury Trade Links
⚡Market Cap: ₹ 33.1 Cr.
⚡Current Price: ₹ 24.3
⚡FII holding: 31.5 %
⚡Chg in FII Hold: 9.48 %
2. GE Vernova T&D India Ltd
⚡Market Cap: ₹ 36,268 Cr.
⚡Current Price: ₹ 1,416
⚡FII holding: 12.0 %
⚡Chg in FII Hold: 5.22 %
3. One Point One Ltd
⚡Market Cap: ₹ 1,251 Cr.
⚡Current Price: ₹ 49.0
⚡FII holding: 16.5 %
⚡Chg in FII Hold: 13.3 %
4. GMM Pfaudler Ltd
⚡Market Cap: ₹ 5,015 Cr.
⚡Current Price: ₹ 1,116
⚡FII holding: 19.7 %
⚡Chg in FII Hold: 5.05 %
5. Elitecon International Ltd
⚡Market Cap: ₹ 24.9 Cr.
⚡Current Price: ₹ 206
⚡FII holding: 38.3 %
⚡Chg in FII Hold: 22.8 %
6. Mos Utility Ltd
⚡Market Cap: ₹ 621 Cr.
⚡Current Price: ₹ 249
⚡FII holding: 19.0 %
⚡Chg in FII Hold: 18.0 %
7. Sudarshan Pharma Industries Ltd
⚡Market Cap: ₹ 792 Cr.
⚡Current Price: ₹ 32.9
⚡FII holding: 13.1 %
⚡Chg in FII Hold: 11.7 %
8. Home First Finance Company India
⚡Market Cap: ₹ 8,394 Cr.
⚡Current Price: ₹ 934
⚡FII holding: 37.9 %
⚡Chg in FII Hold: 12.3 %
9. Himatsingka Siede
⚡Market Cap: ₹ 1,614 Cr.
⚡Current Price: ₹ 128
⚡FII holding: 12.1 %
⚡Chg in FII Hold: 8.74 %
10.Pashupati Cotspin Ltd
⚡Market Cap: ₹ 992 Cr.
⚡Current Price: ₹ 629
⚡FII holding: 10.1 %
⚡Chg in FII Hold: 9.69 %
11. Sammaan Capital Ltd
⚡Market Cap: ₹ 9,871 Cr.
⚡Current Price: ₹ 119
⚡FII holding: 27.4 %
⚡Chg in FII Hold; 7.64 %
12. Lerthai Finance Ltd
⚡Market Cap: ₹ 29.1 Cr.
⚡Current Price: ₹ 415
⚡FII holding: 16.1 %
⚡Chg in FII Hold: 16.1 %
13. Balaji Telefilms Ltd
⚡Market Cap: ₹ 688 Cr.
⚡Current Price: ₹ 57.7
⚡FII holding: 25.2 %
⚡Chg in FII Hold: 6.71 %
14. IDFC First Bank Ltd
⚡Market Cap: ₹ 44,432 Cr.
⚡Current Price: ₹ 60.6
⚡FII holding: 27.1 %
⚡Chg in FII Hold: 7.55 %
15. Indiabulls Enterprises Ltd
⚡Market Cap: ₹ 355 Cr.
⚡Current Price: ₹ 18.0
⚡FII holding: 17.2 %
⚡Chg in FII Hold: 17.1 %
Goldiam International Ltd. aims to expand its store fleet to around 150-200 within the next three to five years.
Speaking to NDTV Profit, the company's Managing Director, Anmol Bhansali, said that they are looking to add 20 to 25 stores, predominantly in three to four metro regions, by the end of the calendar year 2025.
"We have plans to open 20 to 25 stores in the calendar year 2025, not FY25, which is dominant and focussed in all 3-4 metro regions of India," he said.
Now that the Dec-24 results season is over, let’s look at companies with EXCELLENT RESULTS!
CLEAN ENERGY
1. Alpex Solar
2. Australian Premium
3. KP Energy
4. KPI Green Energy
5. Shakti Pumps
6. Websol
TELECOM / SOLAR / POWER INFRA
7. Advait
8. Transrail Lighting
9. Viviana Power
CONSUMPTION
10. Cantabil Retail
11. Khazanchi Jewellers
12. Kings Infra
13. MRP Agro
14. PN Gadgil
15. PNGS Gargi
16. Sky Gold
17. Thomas Scott
18. Vintage Coffee
19. Integrated Industries
CAPITAL GOODS - ELECTRICAL EQUIPMENT
20. Bharat Bijlee
21. Genus Power
22. Indo Tech Transformers
23. KRN Heat Exchanger
24. Power Mech Projects
25. Shilchar Technologies
26. Skipper
27. TD Power Systems
28. Transformers & Rectifiers
CAPITAL GOODS - NON-ELECTRICAL EQUIPMENT
29. Action Construction Equipment
30. Balu Forge
31. Crown Lifters
32. D&H India
33. Kilburn Engineering
34. Tega Industries
35. Tembo Global
36. Texmaco Rail
37. Rungta Irrigation
5G
38. Frog Cellsat
39. Kore Digital
40. Tejas Networks
Copied from stockaajorkal telegram channel
DEFENCE
41. Apollo Micro
42. Premier Explosives
INFORMATION TECHNOLOGY
43. Ceinsys Tech
44. Cigniti Technologies
45. One Point One Solutions
46. Zaggle Prepaid
47. Genesys International
48. DC Infotech
TECH PLATFORM
49. Cartrade Tech
50. Vasa Denticity
NBFC
51. Emerald Finance
52. Home First
SHIPPING / LOGISTICS
53. S J Logistics
54. Tara Chand
SPECIALITY CHEMICALS
55. Sigachi Industries
56. Vishnu Chemicals
DIVERSIFIED COMMERCIAL SERVICES
57. EFC (I)
58. ANI Integrated
Copied from stockaajorkal telegram channel
HEALTHCARE - HOSPITALS / DIAGNOSTICS
59. One Global Service Provider
EPC
60. RBM
HOTELS AND HOSPITALITY
61. Kamat Hotels
MARINE SERVICES
62. Knowledge Marine
OIL & GAS
63. Deep Industries
REALTY
64. Capacite
STEEL PRODUCTS
65. Aeroflex Industries
SUSTAINABILITY AND RECYCLING
66. Gravita
WIRES AND CABLES
67. Dynamic Cables
MISCELLANEOUS
68. Swan Energy
69. Refex Industries
JOIN for more updates
@Fundamental3
Now that the Dec-24 results season is over, let’s look at companies with EXCELLENT RESULTS!
CLEAN ENERGY
1. Alpex Solar
2. Australian Premium
3. KP Energy
4. KPI Green Energy
5. Shakti Pumps
6. Websol
TELECOM / SOLAR / POWER INFRA
7. Advait
8. Transrail Lighting
9. Viviana Power
CONSUMPTION
10. Cantabil Retail
11. Khazanchi Jewellers
12. Kings Infra
13. MRP Agro
14. PN Gadgil
15. PNGS Gargi
16. Sky Gold
17. Thomas Scott
18. Vintage Coffee
19. Integrated Industries
CAPITAL GOODS - ELECTRICAL EQUIPMENT
20. Bharat Bijlee
21. Genus Power
22. Indo Tech Transformers
23. KRN Heat Exchanger
24. Power Mech Projects
25. Shilchar Technologies
26. Skipper
27. TD Power Systems
28. Transformers & Rectifiers
CAPITAL GOODS - NON-ELECTRICAL EQUIPMENT
29. Action Construction Equipment
30. Balu Forge
31. Crown Lifters
32. D&H India
33. Kilburn Engineering
34. Tega Industries
35. Tembo Global
36. Texmaco Rail
37. Rungta Irrigation
5G
38. Frog Cellsat
39. Kore Digital
40. Tejas Networks
Copied from stockaajorkal telegram channel
DEFENCE
41. Apollo Micro
42. Premier Explosives
INFORMATION TECHNOLOGY
43. Ceinsys Tech
44. Cigniti Technologies
45. One Point One Solutions
46. Zaggle Prepaid
47. Genesys International
48. DC Infotech
TECH PLATFORM
49. Cartrade Tech
50. Vasa Denticity
NBFC
51. Emerald Finance
52. Home First
SHIPPING / LOGISTICS
53. S J Logistics
54. Tara Chand
SPECIALITY CHEMICALS
55. Sigachi Industries
56. Vishnu Chemicals
DIVERSIFIED COMMERCIAL SERVICES
57. EFC (I)
58. ANI Integrated
Copied from stockaajorkal telegram channel
HEALTHCARE - HOSPITALS / DIAGNOSTICS
59. One Global Service Provider
EPC
60. RBM
HOTELS AND HOSPITALITY
61. Kamat Hotels
MARINE SERVICES
62. Knowledge Marine
OIL & GAS
63. Deep Industries
REALTY
64. Capacite
STEEL PRODUCTS
65. Aeroflex Industries
Copied from stockaajorkal telegram channel
SUSTAINABILITY AND RECYCLING
66. Gravita
WIRES AND CABLES
67. Dynamic Cables
MISCELLANEOUS
68. Swan Energy
69. Refex Industries
JOIN for more updates
@Fundamental3
IOC says
👍 Confident of receiving subsidy relief for LPG
🤩 Signs of demand improved in Q4 vs Q3/Q2
👍 Diesel cracks are improving; GRMs are recovering and looking better in Q4
